Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
BMC Cardiovasc Disord ; 12: 63, 2012 Aug 06.
Artigo em Inglês | MEDLINE | ID: mdl-22867422

RESUMO

BACKGROUND: The importance of doxorubicin (Dox), as a potent antitumor antibiotic, is limited by the development of life-threatening cardiomyopathy. It has been shown that free radicals are involved in acute doxorubicin-induced toxicity. The aim of this study was to determine the protective effect of vitamin E and telmisartan in acute doxorubicin induced cardiotoxicity. METHODS: Thirty two male Sprague - Dawley rats were involved in this study and were randomly separated into 4 groups, eight rats in each group, one group received normal saline I.P as control and second group received doxorubicin 20 mg/kg I.P, the other two groups also received doxorubicin 20 mg/kg I.P as single dose after seven cumulative doses (for seven days) of vitamin E (100 mg/kg) and telmisartan (1 mg/kg) respectively. Immunofluorescent staining for monocytes infiltration and analyses of plasma by (ELISAs) for MCP-1and troponin I. Western immunoblotting assay for ICAM-1, while left ventricular function was analyzed by microcatheter, also estimated the level of oxidative stress parameters (MDA and Catalase) and cardiac enzymes activities (CK-MB and LDH) before starting drugs treatment and after treatment period by 48 hours. RESULTS: The immunofluorescent staining showed that administration of vitamin E and telmisartan are attenuated of mononuclear cell infiltration; (p < 0.05 vs. Dox group), also reduced the level of chemokines MCP-1 and ICAM-1 expression compared with Dox group only, and there is marked reduction of myocardial troponin-I levels with improved LV function in vitamin E and telmisartan treated group. Doxorubicin treatment increased MDA, LDH, CK-MB levels significantly (P < 0.01), and were counteracted by administration of vitamin E and telmisartan, but did not significantly affect serum catalase activity. CONCLUSIONS: Antioxidant effect (vitamin E and telmisartan) have been shown to decrease doxorubicininduced cardiotoxicity.


Assuntos
Anti-Inflamatórios/farmacologia , Antioxidantes/farmacologia , Benzimidazóis/farmacologia , Benzoatos/farmacologia , Quimiocina CCL2/sangue , Cardiopatias/prevenção & controle , Mediadores da Inflamação/sangue , Molécula 1 de Adesão Intercelular/sangue , Vitamina E/farmacologia , Animais , Western Blotting , Cateterismo Cardíaco , Catalase/sangue , Creatina Quinase Forma MB/sangue , Modelos Animais de Doenças , Regulação para Baixo , Doxorrubicina , Ensaio de Imunoadsorção Enzimática , Imunofluorescência , Cardiopatias/sangue , Cardiopatias/induzido quimicamente , Cardiopatias/imunologia , Cardiopatias/fisiopatologia , L-Lactato Desidrogenase/sangue , Macrófagos/efeitos dos fármacos , Macrófagos/imunologia , Masculino , Malondialdeído/sangue , Miocárdio/imunologia , Miocárdio/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley , Telmisartan , Fatores de Tempo , Troponina I/sangue , Função Ventricular Esquerda/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...